Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

July 10, 2022

A compass to MS Care Rural America – from Lynchburg, VA

  • MS Drug Therapies
    /
  • MS Educational Programs
    /
  • Multiple Sclerosis
    /
  • Multiple Sclerosis Videos
    /
  • Wellness for MS
    /
  Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
MS Drug Therapies

July 9, 2022

Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?

  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
 June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…
MS Drug Therapies

July 8, 2022

Ocrelizumab Reduces Thalamic Volume Loss

  • Additional MS resource sites
    /
  • MS Research Study and Reports
    /
Ocrelizumab Reduces Thalamic Volume Loss, – Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences Using the phase 3…
Additional MS resource sites

July 6, 2022

Biosimilar and Interchangeable Biologics: More Treatment Choices

  • MS Specialty Pharmacy
    /
  • Multiple Sclerosis
    /
The U.S. Food and Drug Administration has approved biosimilar medications to treat conditions such as cancer, diabetes, Crohn’s disease, colitis,…
MS Specialty Pharmacy

July 6, 2022

UK Study: Fatigue Often Influences Quality of Life in MS

  • Multiple Sclerosis
    /
  • Multiple Sclerosis (MS) Symptoms
    /
 by Lindsey Shapiro, PhD | June 30, 2022 Fatigue is a common symptom among people living with multiple sclerosis (MS),…
Multiple Sclerosis

July 4, 2022

Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.

  • MS Research Study and Reports
    /
 Paris, June 30, 2022. The U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS)…
MS Research Study and Reports

July 4, 2022

Peace out: Roche’s Genentech adopts V hand signal in next-gen Ocrevus campaign for multiple sclerosis

  • Ocrevus
    /
Beth Snyder Bulik -Senior Editor The two-finger V sign debuted in Roche’s Genentech first TV commercial for multiple sclerosis treatment…
Ocrevus

June 26, 2022

Brain age as a surrogate marker for cognitive performance in multiple sclerosis

  • Aging & MS
    /
  • MS Research Study and Reports
    /
Information provided by:  Gavin Giovannoni, aka Prof G  @GavinGiovannoni Are you ready for some hard-to-process information about the impact of…
Aging & MS

June 23, 2022

Biogen Secures Tecfidera Patent in EU Until 2028

  • MS Drug Therapies
    /
 Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for multiple sclerosis (MS) through 2028,…
MS Drug Therapies

June 23, 2022

A 5-Step Stretching Routine to Boost Energy and Mobility

  • Complementary & Alternative therapies and devices for Multiple Sclerosis (MS)
    /
 Keeping muscles limber is important for healthy movement, avoiding injury, and aging well. Here’s how to get started today. By…
Complementary & Alternative therapies and devices for Multiple Sclerosis (MS)

Categories

Latest Blog Posts